|
1
|
Vogel A, Meyer T, Sapisochin G, Salem R
and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
3
|
Chidambaranathan-Reghupaty S, Fisher PB
and Sarkar D: Hepatocellular carcinoma (HCC): Epidemiology,
etiology and molecular classification. Adv Cancer Res. 149:1–61.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Y, Yang Y, Zhao Z, Sun H, Luo D,
Huttad L, Zhang B and Han B: A new nomogram model for prognosis of
hepatocellular carcinoma based on novel gene signature that
regulates cross-talk between immune and tumor cells. BMC Cancer.
22:3792022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Icard P, Shulman S, Farhat D, Steyaert JM,
Alifano M and Lincet H: How the Warburg effect supports
aggressiveness and drug resistance of cancer cells? Drug Resist
Updat. 38:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han X, Ren C, Yang T, Qiao P, Wang L,
Jiang A, Meng Y, Liu Z, Du Y and Yu Z: Negative regulation of
AMPKα1 by PIM2 promotes aerobic glycolysis and tumorigenesis in
endometrial cancer. Oncogene. 38:6537–6549. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang D, Tang Z, Huang H, Zhou G, Cui C,
Weng Y, Liu W, Kim S, Lee S, Perez-Neut M, et al: Metabolic
regulation of gene expression by histone lactylation. Nature.
574:575–580. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang H, Chen K, Zhu Y, Hu Z, Wang Y, Chen
J, Li Y, Li D and Wei P: A multi-dimensional approach to unravel
the intricacies of lactylation related signature for prognostic and
therapeutic insight in colorectal cancer. J Transl Med. 22:2112024.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang R, Li Y, Lin K, Zheng L, Zhu X,
Huang L and Ma Y: A novel glycolysis-related gene signature for
predicting prognosis and immunotherapy efficacy in breast cancer.
Front Immunol. 16:15128592025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shen C, Suo Y, Guo J, Su W, Zhang Z, Yang
S, Wu Z, Fan Z, Zhou X and Hu H: Development and validation of a
glycolysis-associated gene signature for predicting the prognosis,
immune landscape, and drug sensitivity in bladder cancer. Front
Immunol. 15:14305832024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu Q, Miao D, Song X, Chen Z, Zeng L, Zhao
L, Xu J, Lin Z and Yu F: Glycolysis-related gene signature can
predict survival and immune status of hepatocellular carcinoma. Ann
Surg Oncol. 29:3963–3976. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grinchuk OV, Yenamandra SP, Iyer R, Singh
M, Lee HK, Lim KH, Chow PK and Kuznetsov VA: Tumor-adjacent tissue
co-expression profile analysis reveals pro-oncogenic ribosomal gene
signature for prognosis of resectable hepatocellular carcinoma. Mol
Oncol. 12:89–113. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roessler S, Jia HL, Budhu A, Forgues M, Ye
QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX and Wang XW: A
unique metastasis gene signature enables prediction of tumor
relapse in early-stage hepatocellular carcinoma patients. Cancer
Res. 70:10202–10212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Riaz N, Havel JJ, Makarov V, Desrichard A,
Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH,
et al: Tumor and microenvironment evolution during immunotherapy
with nivolumab. Cell. 171:934–949.e16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rosenberg JE, Galsky MD, Powles T,
Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J,
Perez-Gracia JL, van der Heijden MS, et al: Atezolizumab
monotherapy for metastatic urothelial carcinoma: Final analysis
from the phase II IMvigor210 trial. ESMO Open. 9:1039722024.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng Z, Huang H, Li M, Liang X, Tan Y and
Chen Y: Lactylation-related gene signature effectively predicts
prognosis and treatment responsiveness in hepatocellular carcinoma.
Pharmaceuticals (Basel). 16:6442023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang X, Li X, Cheng Y, Zhou J, Shen B,
Zhao L and Wang J: Comprehensive analysis of the glycolysis-related
gene prognostic signature and immune infiltration in endometrial
cancer. Front Cell Dev Biol. 9:7978262022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang X, Li Y and Chen Y: Development of a
comprehensive gene signature linking hypoxia, glycolysis,
lactylation, and metabolomic insights in gastric cancer through the
integration of bulk and single-cell RNA-Seq data. Biomedicines.
11:29482023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Z, Liu L, Weng S, Guo C, Dang Q, Xu H,
Wang L, Lu T, Zhang Y, Sun Z and Han X: Machine learning-based
integration develops an immune-derived lncRNA signature for
improving outcomes in colorectal cancer. Nat Commun. 13:8162022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshihara K, Shahmoradgoli M, Martínez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sturm G, Finotello F and List M:
Immunedeconv: An R package for unified access to computational
methods for estimating immune cell fractions from bulk
RNA-sequencing data. Methods Mol Biol. 2120:223–232. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maeser D, Gruener RF and Huang RS:
oncoPredict: an R package for predicting in vivo or cancer patient
drug response and biomarkers from cell line screening data. Brief
Bioinform. 22:bbab2602021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ansari A, Ray SK, Sharma M, Rawal R and
Singh P: Tumor mutational burden as a biomarker of immunotherapy
response: An immunogram approach in onco-immunology. Curr Mol Med.
24:1461–1469. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maggs L, Sadagopan A, Moghaddam AS and
Ferrone S: HLA class I antigen processing machinery defects in
antitumor immunity and immunotherapy. Trends Cancer. 7:1089–1101.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu C, Xia D, Wang D, Wang S, Sun Z, Xu B
and Zhang D: TCOF1 coordinates oncogenic activation and rRNA
production and promotes tumorigenesis in HCC. Cancer Sci.
113:553–564. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen P, Liu Y, Ma X, Li Q, Zhang Y, Xiong
Q and Song T: Replication factor C4 in human hepatocellular
carcinoma: A potent prognostic factor associated with cell
proliferation. Biosci Trends. 15:249–256. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu L, Li J, Zhang M, Li Y, Bai J, Liu P,
Yan J and Wang C: Identification of RFC4 as a potential biomarker
for pan-cancer involving prognosis, tumour immune microenvironment
and drugs. J Cell Mol Med. 28:e184782024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chi G, Pei JH and Li XQ: RAE1 is a
prognostic biomarker and is correlated with clinicopathological
characteristics of patients with hepatocellular carcinoma. BMC
Bioinformatics. 23:2522022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wei S, Lu C, Mo S, Huang H, Chen M, Li S,
Kong L, Zhang H, Hoa PTT, Han C and Luo X: Silencing of KIF2C
enhances the sensitivity of hepatocellular carcinoma cells to
cisplatin through regulating the PI3K/AKT/MAPK signaling pathway.
Anticancer Drugs. 35:237–250. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Amisaki M, Yagyu T, Uchinaka EI, Morimoto
M, Hanaki T, Watanabe J, Tokuyasu N, Sakamoto T, Honjo S and
Fujiwara Y: Prognostic value of DEPDC1 expression in tumor and
non-tumor tissue of patients with hepatocellular carcinoma.
Anticancer Res. 39:4423–4430. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guo W, Li H, Liu H, Ma X, Yang S and Wang
Z: DEPDC1 drives hepatocellular carcinoma cell proliferation,
invasion and angiogenesis by regulating the CCL20/CCR6 signaling
pathway. Oncol Rep. 42:1075–1089. 2019.PubMed/NCBI
|
|
37
|
Wang X, Peng H, Zhang G, Li Z, Du Z, Peng
B and Cao P: ADNP is associated with immune infiltration and
radiosensitivity in hepatocellular carcinoma for predicting the
prognosis. BMC Med Genomics. 16:1782023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fan Q, Yang L, Zhang X, Ma Y, Li Y, Dong
L, Zong Z, Hua X, Su D, Li H and Liu J: Autophagy promotes
metastasis and glycolysis by upregulating MCT1 expression and
Wnt/β-catenin signaling pathway activation in hepatocellular
carcinoma cells. J Exp Clin Cancer Res. 37:92018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Riley RS, June CH, Langer R and Mitchell
MJ: Delivery technologies for cancer immunotherapy. Nat Rev Drug
Discov. 18:175–196. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang
P and Liu XS: Large-scale public data reuse to model immunotherapy
response and resistance. Genome Med. 12:212020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu L, Bai X, Wang J, Tang XR, Wu DH, Du
SS, Du XJ, Zhang YW, Zhu HB, Fang Y, et al: Combination of TMB and
CNA stratifies prognostic and predictive responses to immunotherapy
across metastatic cancer. Clin Cancer Res. 25:7413–7423. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zanfardino M, Pane K, Mirabelli P,
Salvatore M and Franzese M: TCGA-TCIA impact on radiogenomics
cancer research: A systematic review. Int J Mol Sci. 20:60332019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang B, Jiang H, Wu J, Cai Y, Dong Z,
Zhao Y, Hu Q, Hu K, Sun A and Ge J: m6A demethylase FTO attenuates
cardiac dysfunction by regulating glucose uptake and glycolysis in
mice with pressure overload-induced heart failure. Signal Transduct
Target Ther. 6:3772021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Peng J, Cui Y, Xu S, Wu X, Huang Y, Zhou
W, Wang S, Fu Z and Xie H: Altered glycolysis results in
drug-resistant in clinical tumor therapy. Oncol Lett. 21:3692021.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang ZW, Zhang XN, Zhang L, Liu LL, Zhang
JW, Sun YX, Xu JQ, Liu Q and Long ZJ: STAT5 promotes PD-L1
expression by facilitating histone lactylation to drive
immunosuppression in acute myeloid leukemia. Signal Transduct
Target Ther. 8:3912023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang F, Wang B, Zhang W, Xu Y, Zhang C
and Xue X: Transcription factor MAZ potentiates the upregulated
NEIL3-mediated aerobic glycolysis, thereby promoting angiogenesis
in hepatocellular carcinoma. Curr Cancer Drug Targets.
24:1235–1249. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yuen VW and Wong CC: Hypoxia-inducible
factors and innate immunity in liver cancer. J Clin Invest.
130:5052–5062. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang B and Pu R: Association between
glycolysis markers and prognosis of liver cancer: A systematic
review and meta-analysis. World J Surg Oncol. 21:3902023.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang Y, Wang G, Hu S, Yin C, Zhao P, Zhou
X, Shao S, Liu R, Hu W, Liu GL, et al: FARSB facilitates
hepatocellular carcinoma progression by activating the mTORC1
signaling pathway. Int J Mol Sci. 24:167092023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kaszak I, Witkowska-Piłaszewicz O,
Niewiadomska Z, Dworecka-Kaszak B, Ngosa Toka F and Jurka P: Role
of cadherins in cancer-a review. Int J Mol Sci. 21:76242020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee G, Wong C, Cho A, West JJ, Crawford
AJ, Russo GC, Si BR, Kim J, Hoffner L, Jang C, et al: E-cadherin
induces serine synthesis to support progression and metastasis of
breast cancer. Cancer Res. 84:2820–2835. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hashemi M, Arani HZ, Orouei S, Fallah S,
Ghorbani A, Khaledabadi M, Kakavand A, Tavakolpournegari A, Saebfar
H, Heidari H, et al: EMT mechanism in breast cancer metastasis and
drug resistance: Revisiting molecular interactions and biological
functions. Biomed Pharmacother. 155:1137742022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Xie B, Xu S, Schecterson L, Gumbiner BM
and Sivasankar S: Strengthening E-cadherin adhesion via
antibody-mediated binding. Structure. 32:217–227.e3. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liao H, Chang X, Gao L, Ye C, Qiao Y, Xie
L, Lin J, Cai S and Dong H: IL-17A promotes tumorigenesis and
upregulates PD-L1 expression in non-small cell lung cancer. J
Transl Med. 21:8282023. View Article : Google Scholar : PubMed/NCBI
|
